SNDX insider buying & filings

SNDXSyndax Pharmaceuticals Inc

—

$18.18

-1.42% · Sep 15

29 insider filings on record.
None of them an open-market buy in the last year.

Last Form 4 Feb 10 · scanned 7m ago

Price · 1Y · daily● 4 sells

▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

Short % float

Pro

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Feb 10SELLMetzger Michael AChief Executive Officerdirect17,159 @ $21.03$360.8K

Feb 10SELLGoldan Keith A.Chief Financial Officerdirect3,410 @ $21.03$71.7K

Feb 6SELLMetzger Michael AChief Executive Officerdirect7,412 @ $20.62$152.8K

Feb 6SELLGoldan Keith A.Chief Financial Officerdirect2,082 @ $20.62$42.9K

Feb 6GRANTRizo AleksandraDirectordirect24,000 sh—

Context

Wall St

$39.00 avg target

+114.5% vs today · 12 analysts

▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice

Earnings · EPS vs forecast

3 of 4 quarters beat

Q1 '26−$0.48 act+$0.11

Q4 '25−$0.78 act−$0.20

Q3 '25−$0.70 act+$0.01

Q2 '25−$0.83 act+$0.18

Coverage

The file stays open

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice